Back to News
Market Impact: 0.35
Oral Presentation: Ivonescimab Versus Pembrolizumab in First-Line PD-L1-Positive NSCLC: Positive Overall Survival Results from HARMONi-2 at WCLC 2026
Source: PR Newswire
Healthcare & BiotechCorporate Guidance & Outlook
Akeso announced positive overall-survival results from its randomized, double-blind, multicenter registrational Phase III HARMONi-2 (AK112-303) lung-cancer study at the 2026 World Conference on Lung Cancer. The positive Phase III survival data could support the development and potential commercialization outlook for AK112, although the release excerpt provided no efficacy magnitudes, safety details, or regulatory timeline.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.45
More News
- Grab aims for 'next level' in financial services with purchase of buy-now pay-later platform Atome
- Karin Rådström is steering Daimler Truck in a new direction as the world’s biggest truckmaker faces a growing challenge from China
- Is Amazon Stock a Buy After Its Best Quarter in Years?
- Push for AI regulation mounts as talk of AI’s ‘existential’ risks go mainstream. But Trump resists calls for a slowdown
- Wells Fargo sees improvement in a key metric — plus, Lilly gets praise beyond GLP-1s
- Hong Kong unveils first five-year plan to add jobs, homes, align closer to mainland China